Bioprocessing

In a strategic move to tackle severe blood cancers, Alanis Therapeutics (ATI) has teamed up with KBI Biopharma to enhance the development and manufacturing of ATI's preclinical antibody candidate, ATI-D1. This partnership aims to accelerate the treatment of myelodysplastic syndromes (MDS) and

The upstream bioprocessing market is experiencing unprecedented growth, driven by a confluence of factors that are reshaping the landscape of biopharmaceutical production. Valued at 22.79 billion USD in 2023, the market is projected to surge to 82.10 billion USD by 2032, expanding at a compound

The article "Cardiovascular disease risk linked to early brain decline in men," published in the Journal of Neurology Neurosurgery & Psychiatry, examines the correlation between cardiovascular disease risk factors and brain health decline, with a specific focus on gender differences.

The global market for single-use bioreactors (SUBs) is poised for significant growth, with projections indicating an increase from USD 4.4 billion in 2024 to USD 9.1 billion by 2029. This remarkable expansion, driven by a compound annual growth rate (CAGR) of 15.4%, underscores the transformative

The upstream bioprocessing market is experiencing unprecedented growth, with projections indicating a surge from USD 24.16 billion in 2023 to an astounding USD 105.30 billion by 2034. This remarkable expansion is driven by several key factors, including the rising demand for biopharmaceuticals,

In the quest for a sustainable future, the bioeconomy emerges as a significant solution, aiming to replace finite petrochemical resources with renewable resources produced by living organisms. This vision is driven by the need to create a circular economy where products and materials are fully